未找到相关数据
Managing Bone Health in Breast Cancer
被引：4
|作者：
Kearns, Ann E.
[1
,2
]
机构：
[1] Mayo Clin, Div Endocrinol, Rochester, MN USA
[2] Mayo Clin, Div Endocrinol, 200 1st St SW, Rochester, MN 55905 USA
关键词：
breast cancer;
osteoporosis;
aromatase inhibitor;
bisphosphonate;
denosumab;
estrogen;
Introduction;
ADJUVANT ENDOCRINE THERAPY;
PLUS ZOLEDRONIC ACID;
SEX STEROID-LEVELS;
POSTMENOPAUSAL WOMEN;
MINERAL DENSITY;
CONTINUED TAMOXIFEN;
PREMENOPAUSAL WOMEN;
DOUBLE-BLIND;
FOLLOW-UP;
ZO-FAST;
D O I：
10.1016/j.eprac.2022.12.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ;
100201 ;
摘要：
Objective: Osteoporosis is a common condition that can be caused or exacerbated by estrogen deficiency.Methods: This narrative review will discuss optimizing bone health in the setting of adjuvant endocrine treatments for hormone receptor-positive breast cancer and the current use of anti-resorptive agents as adjuvant therapy and as bone modifying agents.Results: Adjuvant endocrine treatments for hormone receptor-positive breast cancer (tamoxifen and aromatase inhibitors) affect bone health. The exact effect depends on the agent used and the menopausal state of the woman. Antiresorptive medications for osteoporosis, bisphosphonates and denosumab, lower the risk of bone loss from aromatase inhibitors. Use of bisphosphonates as adjuvant treatment in breast cancer, regardless of hormone receptor status, is increasing because of benefits seen to cancer relapse and survival.Conclusion: Optimizing bone health in women with breast cancer during and after cancer treatment is informed by an understanding of breast cancer treatment and its skeletal effect.(c) 2022 AACE. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：408 / 413
页数：6
相关论文